AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT06647667 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: MICT
Description: Frequency: Moderate continuous training is scheduled 2 times per week for 12 weeks.~Intensity: exercise had been applied on the treadmill with 40%-59% of heart rate reserve) session duration from 30-40 min including the warming up and cooling down
Study NCT05212662 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TTI-0102
Description: The study treatment is a precursor to cysteamine, TTI-0102 (cysteamine-pantetheine disulfide). Each molecule of TTI-0102, after reduction and metabolism in the digestive tract, allows the absorption of 2 molecules of cysteamine and one molecule of pantothenic acid (Vit B5). Each dose of TTI-0102 comes in a vial as a powder to dissolve in water and absorb orally. Each vial contains 5.5g of TTI-0102, corresponding to the equivalent of 2.4g of cysteamine base. This single dose is less than the maximum daily dose authorized with other formulations of cysteamine (Cystagon or Procysbi, 1.95 g/m2/day) for patients over 1.25 m2 or 40 kg (88 lbs).~This dose of 5.5 g is justified by the need to maintain a thiol/disulfide ratio in favor of cysteamine over 24 h. It has been tested in healthy volunteers and has no side effects due to the specific pharmacokinetics of cysteamine after administration of TTI-0102.
Study NCT05212662 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo comparator supplied in vials identical to the active intervention, TTI-0102
Study NCT05757427 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Wavelia #2
Description: Patients who are eligible and consent to have an MBI breast scan procedure will be asked to confirm their willingness to participate on the day of the breast scan. The patient will first have an OBCD scan, to reconstruct the external surface of the breast with high-precision, measure the total volume and the vertical extent of the breast before the MBI scan. The MBI scan will be performed on both breasts. The process will include optimization of breast positioning and breast cleaning to remove any transition liquid remaining on the skin.
Study NCT06065384 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: usual care
Description: usual rehabilitation
Study NCT05629611 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Vi-Sealer
Description: using Reusable device, Vi-Sealer
Study NCT05629611 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Ligasure
Description: using Ligasure
Study NCT05629611 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Other AHD
Description: Using other AHDs such as Thunderbeat, Harmonic scalpel, Caiman®, Enseal, etc. except Ligasure
Study NCT05239494 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: DT1 Sphere Contact Lenses
Description: Devices: Dailies Total 1 Sphere Contact Lenses
Study NCT05600270 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Angled guidewire
Description: Cannulation of the common bile duct using an angled-tip guidewire during ERCP
Study NCT05600270 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Straight guidewire
Description: Cannulation of the common bile duct using an straight-tip guidewire during ERCP
Study NCT06342401 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: ENCODE
Description: A panel of microRNA, both cell-free and exosomes, whose expression level is tested from plasma samples from patients with early onset colorectal cancer and non-disease controls.
Study NCT06285214 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: V117957
Description: V117957 1 mg - 1 tablet taken orally at bedtime.
Study NCT06285214 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo to match V117957 tablets - 1 tablet taken orally at bedtime.
Study NCT06585514 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CD19 CAR-T cells
Description: Following lymphodepletion with chemotherapy (cyclophosphamide and fludarabine) patients will be treated with CD19 Chimeric Antigen Receptor (CAR) positive T cells as a single dose.
Study NCT04981691 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: anti-MESO CAR T cells
Description: Autologous genetically modified anti-MESO CAR T cells
Study NCT06284863 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: OTHER
Intervention: Natritional Education Program In Hemodialysis Patients
Description: Impact Of Natritional Education Program In Hemodialysis Patients Interventional Study
Study NCT05201911 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 124I-AT03
Description: IV injection of the radiolabeled compound on day 1 followed by Positron Emission Tomography/Computed Tomography (PET/CT) scanning on Days 2, 4 and 8 to. The first 3 subjects enrolled will have two additional scans on Day 1.
Study NCT05518292 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: rhomboid intercostal block
Description: Ultrasound guided RIB will apply with 10-12 MHz linear ultrasound transducer, in plane technique. Patients will placed in the sitting position. 22G spinal needle needle will be inserted to plane between the rhomboid muscle and intercostal muscles over the T5-6 ribs 2 cm to 3 cm medially from the medial border of the scapula. 20 ml of bupivacaine 0.25% will inject into the fascial plane.
Study NCT05518292 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: serratus anterior plane block
Description: Patients will placed in the lateral position with the diseased side up. A 10-12 MHz linear ultrasound transducer is placed over the mid-clavicular region of the thoracic cage in a sagittal plane. The fifth rib is identified in the mid-axillary line. The following muscles are identified easily overlying the fifth rib: the latissimus dorsi (superficial and posterior), teres major (superior) and serratus muscle (deep and inferior). As an extra-reference point, the thoracodorsal artery is used to aid the identification of the plane superficial to the serratus muscle. The needle (22G spinal needle) will be introduced in-plane with respect to the ultrasound probe targeting the plane superficial to the serratus muscle. Under continuous ultrasound guidance, 20 ml of bupivacaine 0.25% will inject.
Study NCT04121481 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Clinical Investigation on Enhanced Sports Nutrition and Performance Activities by Prodovite VMP35 Supplement
Description: Assess the Sports Nutrition efficacy of Prodovite VMP35 against the Placebo sample
Study NCT04121481 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Clinical Investigation on Enhanced Sports Nutrition and Performance Activities by Prodovite VMP35 Supplement
Description: Assess the Sports Nutrition efficacy of Prodovite VMP35 against the Placebo sample
Study NCT04121481 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Broad Spectrum Safety
Description: Benefits in Sports Nutrition
Study NCT04121481 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Broad Spectrum Safety
Description: Benefits in Sports Nutrition
Study NCT04860960 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hydroxypropyl-beta-cyclodextrin
Description: Dose is 2000 mg/kg body weight provided every 2 weeks intravenously
Study NCT04860960 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 0.5N saline provided every 2 weeks intravenously
Study NCT05414097 — intervention group
Intervention type: OTHER
Intervention: Semi-structured focus group discussions - Women
Description: Semi-structured focus group discussions to explore women's experiences with cervical cancer screening and treatment.
Study NCT05414097 — intervention group
Intervention type: OTHER
Intervention: semi-structured focus groups discussions - Men
Description: Semi-structured focus group discussions to explore partner dynamics related to women's ability to access cancer screening.
Study NCT05414097 — intervention group
Intervention type: OTHER
Intervention: In-depth key stakeholders interviews
Description: In-depth interviews to contextualise findings from women and men focus group discussions.
Study NCT05414097 — intervention group
Intervention type: OTHER
Intervention: Discrete Choice Experiment - Women
Description: Discrete Choice Experiment to determine preferences to different cancer screening models.
Study NCT05414097 — intervention group
Intervention type: OTHER
Intervention: Development and User Pre-testing Workshops
Description: Development and User Pre-testing Workshops to explore acceptability and feasibility of proposed interventions designed using findings from Phases 1 \&2.
Study NCT05431530 — intervention group
Intervention type: PROCEDURE
Intervention: Cytoreductive surgery
Description: Cytoreductive surgery including resection of tumors involving rectosigmoid colon.
Study NCT05034861 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: cCTG
Description: Self-applied home computerized CTG device used twice weekly instead of standard Doppler assessment once weekly.
Study NCT05034861 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Doppler
Description: Standard Doppler assessment provided once weekly in case of late FGR with positive end diastolic flow in the umbilical artery.
Study NCT06648265 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tranexamic Acid (Topical)
Description: Add 250 mg of TXA per liter of Klein\&#39;s Tumescent solution for arm liposculpture
Study NCT06648265 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Tumescent solution with dilute lidocaine and epinephrine
Description: Arm infiltration with traditional Klein\&#39;s tumescent solution
Study NCT06648265 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tumescent solution with dilute lidocaine and epinephrine
Description: Arm infiltration with traditional Klein\&#39;s tumescent solution
Study NCT04693936 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: ACTIVE_COMPARATOR
Intervention: Nutraceutical Combination Plan
Description: Multivitamin (My Total Health) 1 tablet per day Vitamin C (My Immuno) 1 scoop per day Calcium-Magnesium combination (My Calmag) 1 scoop per day Omega 3-6-9 My Omega Krill. 1 capsule per day Glutamine (L-Glutamin \&Chios Mastiha) 1 tablet per day Probiotics 40 billion 1 capsule per day~Nutraceuticals will be received daily along with the patient's customary psoriasis/Hashimoto's disease treatment.
Study NCT04923295 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dapagliflozin 10Mg Tab
Description: Effect of Dapagliflozin on ultrafiltration and PET results among peritoneal dialysis patients
Study NCT06205732 — intervention group
Intervention type: OTHER
Intervention: Immunotherapy, targeted therapy.
Description: Immunotherapy (sintilimab, camrelizumab, tislelizumab, atezolizumab, durvalumab, cardenilumab, and pembrolizumab); targeted therapy (apatinib, lenvatinib, sorafenib, and regorafenib).
Study NCT05125523 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sirolimus for Injection (Albumin Bound)
Description: Sirolimus for Injection (Albumin Bound), intravenously, once a week, 28 days per cycle (three weeks-on and one week-off)
Study NCT06647654 — intervention group
Intervention type: BIOLOGICAL
Intervention: ABRYSVO
Description: Test Negative Design: This is a non-interventional retrospective study; therefore, ABSYRVO vaccine has already been administered according to the standard of care. ABRYSVO is a bivalent RSV prefusion F protein-based vaccine (RSVpreF) composed of two prefusion F proteins to protect against both RSV-A and RSV-B.~Ecologic Before-and-After Design: This is an ecologic before-and-after study using aggregated data; as such, the 'exposure' of interest is time before ABRYSVO program implementation (i.e., five historical pre-ABRYSVO RSV seasons) and time after ABRYSVO implementation (i.e., post-ABRYSVO RSV seasons: 2024-2026).
Study NCT05596513 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: motor learning and occupational therapy
Description: 1. Constraint-induced movement therapy (CIMT)~2. Hand-arm bimanual intensive training (HABIT)
Study NCT05596513 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Motor Learning Approaches From Working on a Vertical Surface
Description: 1. Ball on wall, kneel to stand~2. Kneel walk cross over~3. Vertical playground puzzles and games~4. Color on big boxes~5. Fridge magnets~6. Erasing a whiteboard or chalkboard~7. Tactile feedback from textured walls
Study NCT05012475 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Modified Virtual Reality Gaming
Description: Investigators customize each gaming session based on the motivators and interests of each participant. The intervention facilitates independent hand separations (minimizing stereotypies) and encourages independent arm/hand movement that serves to activate or control the computer-generated activities.
Study NCT05137379 — intervention group
Intervention type: BEHAVIORAL
Intervention: A joint functional score based on the affected joint
Description: A joint function score according to the affected joint in patients with Ehlers-Danlos syndrome treated by surgery,: Shoulder (SSV; QuickDash), Knee (Lysholm tenger), Ankle (EFAS), Elbow and wrist (QuickDash) )
Study NCT06388811 — intervention group
Intervention type: OTHER
Intervention: Early Osteoarthritis Questionnaire
Description: Self administered questionnaire
Study NCT04879459 — intervention group
Intervention type: OTHER
Intervention: Practical sessions to learn CUS exclusively on volunteers presenting a healthy gallbladder
Description: The study days are 1 day apart for CG and IG but follow the exact same organization. Studytake place on day 0-10-30 (+/-2days). Practical sessions to learn CUS are organized either on volunteers presenting a healthy gallbladder or a pathological gallbladder (sludge, gallstones) (CG), either exclusively on volunteers presenting a healthy gallbladder (IG).
Study NCT04703296 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: MBAT course
Description: The MBAT will involve:~(i) 4 weekly 1.5-hour course sessions. The sessions will provide guided exercises, didactic information, and discussions to promote greater mindfulness.~(ii) Daily mindfulness practice that will be facilitated by the Measuring Mindfulness App (MMA) and/or instructor-delivered mindfulness practices. The daily mindfulness practice will require about 15 minutes to complete.
Study NCT06456099 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ultrasound-guided corticosteroid injection
Description: Participants will receive one ultrasound-guided injection with 1 ml Kenalog 40mg/ml and 1 ml Lidocaine 10mg/ml superficial to the insertion of the gluteus medius and minimus tendons on the greater trochanter of the hip at baseline, Prior to the beginning of exercises.
Study NCT06456099 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Home exercise program
Description: Our exercise protocol is based on previous literature and expert opinions that has been synthesized in a Delphi study conducted by our research group. The exercise program consists of three body weighted strength exercises, that are to be performed every second day for a period of eight weeks (see appendix 6, Træningsvejledning). Exercise instructions will be available as a handout and online with video instructions. The corticosteroid injection usually causes a flare-up in pain with a duration of up to 48 hours. Participants will be instructed to begin the exercises as soon as possible after this flare-up has settled. Compliance to exercises are measured using a training diary that the participants must fill out during the study period (see appendix 7, Træningsdagbog).
Study NCT06456099 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Patient information leaflet
Description: In order to support self-management and modification of tendon load, participants will receive a handout at baseline that contains information about GTPS and advice on load management (see appendix 8, Folder - Smerter på ydersiden af hoften). The participants will be encouraged to read the leaflet regularly and follow the advice.
Study NCT04811053 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HR021618
Description: Treatment group A: HR021618 injection
Study NCT04811053 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Treatment group B: Saline injection
Study NCT05966935 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Fenugreek Cumin Powder
Description: Fenugreek and Cumin seeds will be procured from the market. They will be cleaned of debris, winnowed, and grinded to fine powder passed through a mesh size of 30 for metal cleaning. 5g of fenugreek powder and 5g of cumin powder will be packed in packets. Participants in the intervention group will be instructed to consume the powder before breakfast and dinner with a glass of water.
Study NCT05745428 — intervention group
Intervention type: OTHER
Intervention: molecular and cellular analyses
Description: sample blood
Study NCT04588233 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Melatonin
Description: Each subject will receive 3mg of melatonin 1 hour prior to bedtime for 12 consecutive nights
Study NCT04588233 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Each subject will receive a placebo 1 hour prior to bedtime for 12 consecutive nights
Study NCT06051487 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: titanium dioxide nanoparticles in test group
Description: Titanium dioxide nanoparticles added to acrylic baseplate in test group
Study NCT05647551 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BOTOX®/VISTABEL®
Description: Facial Injection
Study NCT05647551 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Juvéderm® VOLBELLA® with Lidocaine
Description: Facial Injection
Study NCT05647551 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Juvéderm® VOLIFT® with Lidocaine
Description: Facial Injection
Study NCT05647551 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Juvéderm® VOLUMA® with Lidocaine
Description: Facial Injection
Study NCT04954586 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pain Informed Movement
Description: Participants will attend a twice weekly exercise program.
Study NCT06178952 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Transcranial pulse stimulation Verum
Description: Participants are slated to undergo a total of five TPS sessions over a 10-day interval. Each stimulation session will endure approximately 30 minutes and will be administered once daily.
Study NCT06178952 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Transcranial pulse stimulation Sham
Description: Placebo treatment will be performed using the same medical device, handpiece and treatment paradigm as in the verum treatment with one difference: the standoff device at the end of the handpiece. This device is designed to replicate the appearance, feel, and sound of the verum system, while omitting the transmission of any pulses.
Study NCT04287725 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: exercise + photobiomodulation therapy
Description: Treatment sessions will be provided twice a week for 6 weeks (totaling 12 sessions) with participants receiving either placebo or active PBMT + exercise protocol.
Study NCT04287725 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: exercise + photobiomodulation therapy
Description: Treatment sessions will be provided twice a week for 6 weeks (totaling 12 sessions) with participants receiving either placebo or active PBMT + exercise protocol.
Study NCT04724629 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Ixekizumab
Description: 80 mg of IL-17 inhibitor
Study NCT04724629 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Aldesleukin
Description: 1.5 million IU (low-dose) of IL-2
Study NCT04724629 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Colchicine
Description: 0.5 mg of indirect IL-6 inhibitor
Study NCT04724629 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Standard of care (SOC)
Description: Active comparator (Corticoids and antiretrovirals)
Study NCT06071143 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: KDSTEM Inj.
Description: 1. Low dose: The following study drugs are pre-mixed with 90mL of 0.9% normal saline and injected intravenously three times over the duration of the study. (Treatment group: KDSTEM Inj. 1.0x10\^8 cells/10mL/2 syringes)~2. High dose: The following study drugs are pre-mixed with 70mL of 0.9% normal saline and injected intravenously three times over the duration of the study. (Treatment group: KDSTEM Inj. 3.0x10\^8 cells/30mL/6 syringes)
Study NCT06488495 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exercise Program
Description: The exercise intervention includes a six-week program with weekly supervised sessions and daily home-based exercises.
Study NCT06488495 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Exercise Program
Description: The exercise intervention includes a six-week program with weekly supervised sessions and daily home-based exercises.
Study NCT06419686 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo (saline)
Description: Intravenous saline during experimental days.
Study NCT06419686 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GIP
Description: Intravenous GIP administration during experimental days.
Study NCT06419686 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Alanine
Description: Intravenous alanine administration during experimental days.
Study NCT06419686 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GIP + alanine
Description: Intravenous administration of GIP and alanine during experimental days.
Study NCT01000220 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Omeprazole
Study NCT01000220 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo